The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy
Authors:
- 3 February 2020
- journal article
- review article
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 15 (2) , 130-132
Abstract
Purpose of Review Chimeric antigen receptor T cell therapy is gaining clinical use in the management of B cell lymphomas. As the use of this unique treatment option increases, its associated toxicities will require recognition and treatment. In this review, we aim to discuss the cardiovascular toxicities of chimeric antigen receptor T cell therapy and our approach to their clinical management. Recent Findings Cardiotoxicity may be due to direct or indirect effects of infused chimeric antigen receptor T cells. The cytokine release syndrome has been described extensively in the literature. Studies have also reported cardiovascular dysfunction including hypotension, left ventricular dysfunction, heart failure, and cardiogenic shock in the setting of cytokine release syndrome. Summary While there are no standardized guidelines for the treatment of cytokine release syndrome or associated cardiotoxicity, we present our current clinical practices. Further research is indicated into the pathophysiology of therapy-associated cardiac dysfunction and effective management strategies to optimize patient outcomes.Keywords
This publication has 6 references indexed in Scilit:
- Chimeric Antigen Receptor T-Cell Therapy for Cancer and HeartJACC, 2019
- Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution ExperienceTransplantation and Cellular Therapy, 2018
- Toxicities of chimeric antigen receptor T cells: recognition and managementBlood, 2016
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Role of interleukin 6 in myocardial dysfunction of meningococcal septic shockThe Lancet, 2004